Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C
- PMID: 22848715
- PMCID: PMC3407113
- DOI: 10.1371/journal.pone.0042094
Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C
Abstract
Ribavirin improves outcomes of therapy in chronic hepatitis C but its mode of action has still remained unclear. Since ribavirin has been proposed to modulate the host's T cell responses, we studied its direct effects on CD4(+) T cell clones with diverse functional polarization which had been generated from patients with chronic hepatitis C. We analysed in vitro proliferation ([(3)H] thymidine uptake) and cytokine responses (IL-10, IFN-gamma) at varying concentrations of ribavirin (0-10 µg/ml) in 8, 9 and 7 CD4(+) TH1, TH2 and regulatory T cell (Treg) clones, respectively. In co-culture experiments, we further determined effects of ribarivin on inhibition of TH1 and TH2 effector cells by Treg clones. All clones had been generated from peripheral blood of patients with chronic hepatitis C in the presence of HCV core protein. Ribavirin enhanced proliferation of T effector cells and increased production of IFN-gamma in TH1 clones, but had only little effect on IL-10 secretion in TH2 clones. However, ribavirin markedly inhibited IL-10 release in Treg clones in a dose dependent fashion. These Treg clones suppressed proliferation of T effector clones by their IL-10 secretion, and in co-culture assays ribavirin reversed Treg-mediated suppression of T effector cells. Our in vitro data suggest that--in addition to its immunostimulatory effects on TH1 cells--ribavirin can inhibit functions of HCV-specific Tregs and thus reverses Treg-mediated suppression of T effector cells in chronic hepatitis C.
Conflict of interest statement
Figures





Similar articles
-
Core-specific adaptive regulatory T-cells in different outcomes of hepatitis C.Clin Sci (Lond). 2010 Apr 20;119(2):97-109. doi: 10.1042/CS20090661. Clin Sci (Lond). 2010. PMID: 20222873
-
The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91. doi: 10.1099/0022-1317-79-10-2381. J Gen Virol. 1998. PMID: 9780043
-
IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease.J Leukoc Biol. 2016 Sep;100(3):613-23. doi: 10.1189/jlb.5A0415-140R. Epub 2016 Feb 26. J Leukoc Biol. 2016. PMID: 26921346
-
IL-10 as a Th2 Cytokine: Differences Between Mice and Humans.J Immunol. 2021 Nov 1;207(9):2205-2215. doi: 10.4049/jimmunol.2100565. J Immunol. 2021. PMID: 34663593 Free PMC article. Review.
-
CD4 T cells: fates, functions, and faults.Blood. 2008 Sep 1;112(5):1557-69. doi: 10.1182/blood-2008-05-078154. Blood. 2008. PMID: 18725574 Free PMC article. Review.
Cited by
-
Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: a randomized clinical trial.PLoS One. 2014 Apr 7;9(4):e93620. doi: 10.1371/journal.pone.0093620. eCollection 2014. PLoS One. 2014. PMID: 24709775 Free PMC article. Clinical Trial.
-
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.Hepatology. 2014 Oct;60(4):1160-9. doi: 10.1002/hep.27092. Epub 2014 Aug 13. Hepatology. 2014. PMID: 24700342 Free PMC article. Clinical Trial.
-
Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Adv Virol. 2013;2013:595768. doi: 10.1155/2013/595768. Epub 2013 Dec 9. Adv Virol. 2013. PMID: 24382964 Free PMC article. Review.
-
Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.Antimicrob Agents Chemother. 2015 Dec 28;60(3):1608-14. doi: 10.1128/AAC.02496-15. Antimicrob Agents Chemother. 2015. PMID: 26711757 Free PMC article.
-
Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.World J Hepatol. 2016 Oct 28;8(30):1287-1294. doi: 10.4254/wjh.v8.i30.1287. World J Hepatol. 2016. PMID: 27843539 Free PMC article.
References
-
- Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567. - PubMed
-
- Aghemo A, Rumi MG, Colombo M (2009) Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 7: 925–935. - PubMed
-
- Lau JYN, Tam RC, Liang TJ, Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35: 1002–1009. - PubMed
-
- Spengler U, Nattermann J (2007) Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci 112: 141–155. - PubMed
-
- Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, et al. (2002) The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36: 743–754. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials